Search clinical trials for: Liposomal paclitaxel

Total 5882 results

National Cancer Institute (NCI)

Recruiting

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study)

Malignant Solid Neoplasm

United States
Shandong Luye Pharmaceutical Co., Ltd.
Nanjing Sike Pharmaceutical Co., Ltd.

Completed

Pharmacokinetics Study of Liposomal Paclitaxel in Humans (LPS-PK-H)

Cancer

China
Ark Biosciences Inc.

Completed

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy Subjects

Healthy Subjects

United States
Bio-Path Holdings, Inc.

Recruiting

BP1001-A in Patients With Advanced or Recurrent Solid Tumors

Fallopian Tube Neoplasms | Carcinoma, Ovarian Epithelial | Solid Tumor | Endometrial Cancer | Peritoneal Cancer | Solid Tumor, Adult

United States
Nanjing Sike Pharmaceutical Co., Ltd.

Unknown

Clinical Study of Liposomal Paclitaxel in Chinese Patients

Solid Tumor

China
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

PNU-93914 in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus

Esophageal Cancer

United States
National Cancer Institute (NCI)

Completed

Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Male Breast Carcinoma | Stage IV Breast Cancer AJCC...

United States
National Cancer Institute (NCI)

Completed

Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma

DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S9912 Combination Chemo in Stage III Ovarian Cancer,

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
National Cancer Institute (NCI)

Completed

Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma

AIDS-related Kaposi Sarcoma

United States
Sun Yat-sen University

Completed

Liposomal Paclitaxel Combined Nedaplatin in Treatment of Advanced or Recurrent Esophageal Carcinoma

Esophageal Carcinoma

China
Hunan Cancer Hospital

Recruiting

Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum-Partial Sensitive Recurrent Ovarian Cancer

Ovarian Cancer

China
Peking Union Medical College
CSPC Ouyi Pharmaceutical Co., Ltd.

Unknown

Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer

Breast Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma
Wake Forest University Health Sciences
National Cancer Institute (NCI); Spectrum Pharmaceuticals, Inc

Terminated

Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia

United States
Borstkanker Onderzoek Groep
Roche Pharma AG; Teva Pharma

Completed

8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer (Stop&Go)

Metastatic Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

Netherlands
Arcus Biosciences, Inc.
Infinity Pharmaceuticals, Inc.

Completed

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

Ovarian Cancer | TNBC - Triple-Negative Breast Cancer

United States, Australia
National Cancer Institute, Naples

Active, not recruiting

MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer

Ovarian Cancer

Italy, Portugal, Turkey
Skaraborg Hospital

Completed

Treatment of BV With Donaxyl and a Molecular Test of Cure

Bacterial Vaginoses
NYU Langone Health
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract

Sarcoma | Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer

United States
Qilu Hospital of Shandong University

Recruiting

Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

China
Nanjing Luye Sike Pharmaceutical Co., Ltd.

Unknown

Dose Escalation and Pharmacokinetic Study of Paclitaxel Liposome Injection in Treating Patients With Advanced Solid Tumor After Failure From Conventional Treatments

Solid Tumors

China
Claudia Lorenz-Schlüter

Terminated

Therapy of Metastatic Breast Cancer With Paclitaxel and Liposomal Doxorubicin (MyoPac)

Metastatic Breast Cancer

Germany
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States, Norway
Aptium Oncology Research Network
Ortho Biotech Products, L.P.

Unknown

Phase II Study in Patients With Operable Breast Cancer

Breast Cancer

United States
King Faisal Specialist Hospital & Research Center

Completed

Multi-national, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse. (CALYPSO)

Epithelial Ovarian Cancer
Nanjing Sike Pharmaceutical Co., Ltd.

Unknown

Dose Escalation Study of Liposomal Paclitaxel Plus Capecitabine in Chinese Patients With Advanced Gastric Carcinoma

Advanced Gastric Carcinoma
Nanjing Sike Pharmaceutical Co., Ltd.

Unknown

Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric Carcinoma

Gastric Carcinoma

China
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Locally Advanced

China
Women's Hospital School Of Medicine Zhejiang University

Active, not recruiting

Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer

Efficacy and Safety

China
Konkuk University Medical Center
National Cancer Center, Korea; Samsung Medical Center; Asan Medical Center; Seoul... and other collaborators

Completed

Real-World Effectiveness of PLD in Platinum- Sensitive Recurrent Ovarian Cancer

Ovarian Carcinoma

Korea, Republic of
Aravive, Inc.

Completed

Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Ovarian Cancer

United States
INSYS Therapeutics Inc

Completed

Comparison of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) and Taxol® Pharmacokinetics in Patients With Advanced Cancer

Neoplasm

United States, Germany, Netherlands
The First Affiliated Hospital with Nanjing Medical...
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer

Esophageal Squamous Cell Carcinoma

China
Peking University

Unknown

Study on Neoadjuvant Chemotherapy for Advanced Gastric Cancer

Advanced Gastric Carcinoma

China
Massachusetts General Hospital
National Cancer Institute (NCI)

Completed

Neoadjuvant Chemotherapy Using Doxorubicin and Paclitaxel in Treating Women With Large Breast Cancer

Breast Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Ovarian Undifferentiated Carcinoma

United States
Sun Yat-sen University

Unknown

Induction Chemotherapy in Young Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Children

China
Sun Yat-sen University

Recruiting

Albumin-bound Paclitaxel Combined With Liposomal Doxorubicin in the Treatment of Advanced or Unresectable Angiosarcoma

Angiosarcoma Metastatic

China
National Cancer Institute (NCI)
NRG Oncology; Canadian Cancer Trials Group

Active, not recruiting

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian... and other conditions

United States, Canada, Puerto Rico, Korea, Republic of, Japan
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

Ovarian Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Recurrent Ovarian Low Grade Serous Adenocarcinoma | Borderline Ovarian Serous Tumor | Micropapillary Serous Carcinoma | Recurrent Primary Peritoneal Serous Adenocarcinoma

United States, United Kingdom
Tesaro, Inc.

Terminated

A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1)

Cancer: Solid Tumors
Fudan University

Not yet recruiting

Efficacy and Safety of Paclitaxel Liposome and S-1 as First-line Therapy in \ Advanced Pancreatic Cancer Patients

Advanced Pancreatic Cancer

China
Nanjing Luye Sike Pharmaceutical Co., Ltd.

Unknown

Weekly and Every 3 Week Administration of Paclitaxel Liposome Injection in Metastatic Breast Cancer

Breast Cancer

China
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

Breast Neoplasms

Korea, Republic of, Germany, United States, United Kingdom, Argentina, Australia, Austria, Brazil, Canada, Chile, China, Colombia, France, Greece, Guatemala, Hungary, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, Phili... and more
Merck Sharp & Dohme LLC

Completed

Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048)

Breast Neoplasm
SOLTI Breast Cancer Research Group

Completed

Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer (Opti-HER)

Breast Cancer

Spain
INSYS Therapeutics Inc

Completed

Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients With Advanced Cancer

Neoplasm

United States
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin Pharma, Inc.

Terminated

Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer

Neoplasms | Ovarian Neoplasms | Fallopian Tube Neoplasms | Primary Peritoneal Neoplasm

United States
Universitaire Ziekenhuizen KU Leuven
AstraZeneca

Active, not recruiting

Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer (CLIO)

Ovarian Epithelial Cancer

Belgium

Search clinical trials for: Liposomal paclitaxel

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations